Advanced

The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients

Walters, E H; Bjermer, Leif LU ; Faurschou, P and Sandstrom, T (2000) In Respiratory Medicine 94(Suppl. 6). p.26-31
Abstract
Inhaled corticosteroid (ICS) therapy such as fluticasone propionate (FP) is effective in moderate-to-severe asthma, but for patients on ICS who still experience symptoms, treatment guidelines recommend either increasing the dose of ICS or adding a long-acting beta2-agonist such as salmeterol or formoterol. Several studies have now shown that adding salmeterol provides greater clinical benefit than increasing the dose of ICS, raising the question of whether salmeterol has an additive or complementary anti-inflammatory effect to that of ICS. Recent studies on bronchial biopsies and bronchoalveolar lavage from asthmatic patients treated with either salmeterol. FP or placebo in addition to low-dose ICS have demonstrated that addition of... (More)
Inhaled corticosteroid (ICS) therapy such as fluticasone propionate (FP) is effective in moderate-to-severe asthma, but for patients on ICS who still experience symptoms, treatment guidelines recommend either increasing the dose of ICS or adding a long-acting beta2-agonist such as salmeterol or formoterol. Several studies have now shown that adding salmeterol provides greater clinical benefit than increasing the dose of ICS, raising the question of whether salmeterol has an additive or complementary anti-inflammatory effect to that of ICS. Recent studies on bronchial biopsies and bronchoalveolar lavage from asthmatic patients treated with either salmeterol. FP or placebo in addition to low-dose ICS have demonstrated that addition of salmeterol produces independent or additional reductions in several pro-inflammatory cells, cytokines and cell adhesion molecules compared with FP. Such complementary anti-inflammatory effects may explain the improved control of asthma symptoms and exacerbations observed when salmeterol is added to low-dose ICS therapy, and may help to modify the long-term sequelae of asthma. These findings also indicate, contrary to earlier speculation, that salmeterol does not have a pro-inflammatory effect or mask persistent airway inflammation. This review presents the results of recent studies and suggests possible mechanisms for the additional antiinflammatory effects of salmeterol. (Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
salmeterol, fluticasone propionate, inhaled corticosteroids, asthma, airway inflammation, leucocytes
in
Respiratory Medicine
volume
94
issue
Suppl. 6
pages
26 - 31
publisher
Elsevier
external identifiers
  • pmid:11059965
  • scopus:0033765164
ISSN
1532-3064
DOI
10.1016/S0954-6111(00)90130-6
language
English
LU publication?
no
id
a8cadd0f-eba2-45b6-bd6b-ec019b49fdf2 (old id 1116640)
date added to LUP
2008-07-02 09:28:43
date last changed
2017-01-01 06:42:25
@article{a8cadd0f-eba2-45b6-bd6b-ec019b49fdf2,
  abstract     = {Inhaled corticosteroid (ICS) therapy such as fluticasone propionate (FP) is effective in moderate-to-severe asthma, but for patients on ICS who still experience symptoms, treatment guidelines recommend either increasing the dose of ICS or adding a long-acting beta2-agonist such as salmeterol or formoterol. Several studies have now shown that adding salmeterol provides greater clinical benefit than increasing the dose of ICS, raising the question of whether salmeterol has an additive or complementary anti-inflammatory effect to that of ICS. Recent studies on bronchial biopsies and bronchoalveolar lavage from asthmatic patients treated with either salmeterol. FP or placebo in addition to low-dose ICS have demonstrated that addition of salmeterol produces independent or additional reductions in several pro-inflammatory cells, cytokines and cell adhesion molecules compared with FP. Such complementary anti-inflammatory effects may explain the improved control of asthma symptoms and exacerbations observed when salmeterol is added to low-dose ICS therapy, and may help to modify the long-term sequelae of asthma. These findings also indicate, contrary to earlier speculation, that salmeterol does not have a pro-inflammatory effect or mask persistent airway inflammation. This review presents the results of recent studies and suggests possible mechanisms for the additional antiinflammatory effects of salmeterol.},
  author       = {Walters, E H and Bjermer, Leif and Faurschou, P and Sandstrom, T},
  issn         = {1532-3064},
  keyword      = {salmeterol,fluticasone propionate,inhaled corticosteroids,asthma,airway inflammation,leucocytes},
  language     = {eng},
  number       = {Suppl. 6},
  pages        = {26--31},
  publisher    = {Elsevier},
  series       = {Respiratory Medicine},
  title        = {The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients},
  url          = {http://dx.doi.org/10.1016/S0954-6111(00)90130-6},
  volume       = {94},
  year         = {2000},
}